The clinical benefits of bacillus Calmette–Guérin (BCG) therapy for the management of
upper urinary tract carcinoma in situ (CIS) remain unclear. We aimed to compare the efficacy …

There are few data on Bacillus Calmette-Guérin (BCG) therapy for upper urinary tract
carcinoma in situ (UUT CIS). We retrospectively evaluated the efficacy and tolerability of …

Background: We examined the long‐term outcome and compared the usefulness of
nephroureterectomy with that of bacillus Calmette‐Guérin (BCG) therapy for the …

Abstract Background and Purpose: While nephroureterectomy (NU) remains the gold-
standard treatment for upper-tract carcinoma in situ (UT-CIS), it may be unnecessarily …

Objective To assess the long‐term efficacy of intrarenal bacillus Calmette‐Guérin (BCG)
therapy for the treatment of cytologically diagnosed upper tract carcinoma in situ (CIS) and …

Background Radical nephroureterectomy (RNU) represents the gold standard treatment for
upper tract urothelial carcinoma (UTUC); however, attempts have been made to treat upper …

Purpose: Carcinoma in situ and urothelial tumors of the upper urinary tract become
problematic in cases of bilateral occurrence or solitary kidney. Perfusions with bacillus …

Simple Summary This retrospective cohort study aimed to understand the incidence, clinical
impact, and risk factors associated with upper urinary tract urothelial carcinoma (UTUC) after …

Objectives: The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus
Calmette–Guérin (BCG) instillation as a treatment for transitional cell carcinoma in situ (CIS) …

Objectives: We analyzed the clinical outcomes of instillation therapy with Bacillus Calmette‐
Guerin (BCG) to treat carcinoma in situ (CIS) and searched for prognostic factors that could …